Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: A novel therapeutic approach for inflammatory bowel disease by exosomes derived from human umbilical cord mesenchymal stem cells to repair intestinal barrier via TSG-6

Fig. 2

MSCs-Exo attenuated DSS-induced acute colitis. a Schematic diagram of the experimental design. Mice were administered with 2.0% DSS continuously for 7 days to induce colitis. Mice were intraperitoneally injected with the same volume of exosomes or PBS at day 5, and sacrificed at day 10. i.p., intraperitoneal. b Hematochezia in the DSS + PBS mice was more serious than mice of the DSS + Exo group at day 7. c Survival rate of mice in the DSS + PBS and DSS + Exo groups (n = 16). The body weight (d) and DAI (e) of mice were recorded daily from day 0 to day 10. Colonic macroscopic images (f), colon length (g), MPO (h), HE staining and histological score (i) in the control, DSS + PBS, and DSS + Exo groups at day 10. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001

Back to article page